Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-06-21
2011-06-21
Hama, Joanne (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023500
Reexamination Certificate
active
07964710
ABSTRACT:
The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
REFERENCES:
patent: 2004/080980 (2004-09-01), None
patent: 2005/009389 (2005-02-01), None
patent: 2005/016894 (2005-02-01), None
patent: 2005/097765 (2005-10-01), None
patent: 2008/127248 (2008-10-01), None
Marc Pollmann, et al.; “Human EML4, a Novel Member of the EMAP Family, is Essential for Microtubule Formation”; Experimental Cell Research; 2006; pp. 3241-3251.
Willy G. Dirks, et al.; “Expression and Functional Analysis of the Anaplastic Lymphoma Kinase (ALK) Gene in Tumor Cell Lines”; International Journal of Cancer; 2002; pp. 49-56; vol. 100.
Stephan W. Morris, et al.; “Fusion of a Kinase Gene,ALK, to a Nucleolar Protein Gene,NPM, in Non-Hodgkin's Lymphoma”; Science; Mar. 4, 1994; pp. 1281-1284; vol. 263.
Mami Shiota, et al.; “Anaplastic Large Cell Lymphomas Expressing the Novel Chimeric Protein p80NPM/ALK: A Distinct Clinicopathologic Entity”; Blood; Sep. 1, 1995; pp. 1954-1960; vol. 86, No. 5.
Christian Touriol, et al.; “Further Demonstration of the Diversity of Chromosomal Changes Involving 2p23 in ALK-positive Lymphoma: 2 cases Expressing ALK Kinase Fused to CLTCL (Clathrin Chain Polypeptide-like)”; Blood; May 15, 2000; pp. 3204-3207; vol. 95, No. 10.
Luis Hernandez, et al.; “TRK-Fused Gene (TFG) Is a New Partner ofALKin Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALKTranslocations”; Blood; Nov. 1, 1999; pp. 3265-3268; vol. 94, No. 9.
Larisa V. Debelenko, et al.; “Identification ofCARS-ALKFusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor”; Laboratory Investigation; Sep. 2003; pp. 1255-1265; vol. 83, No. 9.
Ioannis Panagopoulos, et al.; “Fusion of theSEC31L1andALKGenes in an Inflammatory Myofibroblastic Tumor”; International Journal of Cancer; 2006; pp. 1181-1186; vol. 118.
Roberto Piva, et al.; “Ablation of Oncogenic ALK is a Viable Therapeutic Approach for Anaplastic Large-cell Lymphomas”; Blood; Jan. 15, 2006; pp. 689-697; vol. 107, No. 2.
Weihua Wan, et al.; “Anaplastic Lymphoma Kinase Activity is Essential for the Proliferation and Survival of Anaplastic Large-cell Lymphoma Cells”; Blood; Feb. 15, 2006; pp. 1617-1623; vol. 107, No. 4.
Michal Marzec, et al.; “Inhibition of ALK Enzymatic Activity in T-cell Lymphoma Cells Induces Apoptosis and Suppresses Proliferation and STAT3 Phosphorylation Independently of Jak3”; Laboratory Investigation; 2005; pp. 1544-1554; vol. 85.
Rongshi Li, et al.; “Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase”; Journal of Medicinal Chemistry; 2006; pp. 1006-1015; vol. 49.
Virginie Lacronique, et al.; “A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia”; Science; Nov. 14, 1997; pp. 1309-1312; vol. 278.
GenBank accession No. NM—019063; Source: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?19923496:NCBI:12636854, Retrieved from NCBI Mar. 25, 2009, First published in Heidebrecht, et al., “Cloning and localization of C2orf2(ropp120), a previously unknown WD repeat protein,” Genomics 68 (3), 348-350 (2000).
GenBank accession No. AB209477; Source: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=62088533, Retrieved from NCBI Mar. 25, 2009, 2009, First published in Totoki, et al., “Homo sapiensprotein coding cDNA,” Published only in Database (2005).
Toshinori Iwahara, et al. “Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System”; Oncogene; 1997; pp. 439-449; vol. 14; Stockton Press.
Mami Shiota, et al.; “Hyperphosphorylation of a Novel 80 kDa Protein-tyrosine Kinase Similar to Ltk in a Human Ki-1 Lymphoma Cell Line, AMS3”; Oncogene; 1994; pp. 1567-1574; vol. 9; Macmillan Press, Ltd.
Luis Hernandez, et al.; “Diversity of Genomic Breakpoints inTFG-ALKTranslocations in Anaplastic Large Cell Lymphomas”; American Journal of Pathology; Apr. 2002; pp. 1487-1494; vol. 160, No. 4.
Brandon Lawrence, et al.; “TPM3-ALKandTPM4-ALKOncogenes in Inflammatory Myofibroblastic Tumors”; American Journal of Pathology; Aug. 2, 2000; pp. 377-384; vol. 157, No. 2.
Martin U. Kuefer, et al.; “Retrovirus-Mediated Gene Transfer ofNPM-ALKCauses Lymphoid Malignancy in Mice”; Blood; Oct. 15, 1997; pp. 2901-2910; vol. 90, No. 8.
Gisele W. B. Colleoni, et al.; “ATIC-ALK: A Novel VariantALKGene Fusion in Anaplastic Large Cell Lymphoma Resulting From the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35)”, American Journal of Pathology; Mar. 3, 2000; pp. 781-789; vol. 156, No. 3.
Tong Zhu, et al. “Polymer-Supported Synthesis of Pyridone-Focused Libraries as Inhibitors of Anaplastic Lymphoma Kinase”; Journal of Combinatorial Chemistry; 2006; pp. 401-409; vol. 8, No. 3.
Kojo S.J. Elenitoba-Johnson, et al.; “Proteomic Identification of Oncogenic Chromosomal Translocation Partners Encoding Chimeric Anaplastic Lymphoma Kinase Fusion Proteins”; PNAS; May 9, 2006; pp. 7402-7407; vol. 103, No. 19.
Anna V. Galkin, et al.; “Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK”; PNAS; Jan. 2, 2007; EpubDec. 2006, pp. 270-275; vol. 104, No. 1.
Manabu Soda, et al.; “Identification of the TransformingEML4-ALKFusion Gene in Non-small-cell Lung Cancer”; Nature; Aug. 2, 2007 (online Jul. 11, 2007); pp. 561-567 and 1-11; vol. 448; Nature Publishing Group.
Manabu Soda, et al.; “A Novel Transforming Fusion Kinase Identified in Non-small-cell Lung Cancer”; O-455, Proceedings of the 66th Annual Meeting of the Japanese Cancer Association; Issued Aug. 25, 2007.
Hiroyuki Mano; “A Novel Transforming Fusion Kinase in Lung Cancer”; ML10 Proceedings of the 66th Annual Meeting of the Japanese Cancer Association; Issued Aug. 25, 2007.
Manabu Soda et al., “Retroviral Expression Screening of Oncogenes in Primary Non-small-cell Lung Cancer”; Proceedings of the 65thAnnual Meeting of the Japanese Cancer Association; Aug. 28, 2006.
K. Pulford et al., “Anaplastic Lymphoma Kinase Proteins in Growth Control and Cancer”; Journal of Cellular Physiology; Jun. 2004; 199(3): 330-358.
Furutani Takashi
Kuromitsu Sadao
Mano Hiroyuki
Shindo Nobuaki
Soga Takatoshi
Astellas Pharma Inc.
CureGene K. K.
Hama Joanne
Sughrue & Mion, PLLC
LandOfFree
EML4-ALK fusion gene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EML4-ALK fusion gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EML4-ALK fusion gene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2723403